logo
  

Isuzu Motors Q1 Profit Falls

Isuzu Motors Ltd. (ISUZY.PK), a Japanese commercial vehicle and diesel engine maker, on Friday posted a decline in earnings for the first quarter.

For the three-month period to June, the Yokohama headquartered firm reported a net profit of 36.05 billion yen or 46.51 yen per share, compared with 46.42 billion yen or 60.05 yen per share a year ago.

Profit before income taxes was at 58.36 billion yen, lesser than 61.81 billion yen of previous year period.

Operating earnings were at 54.77 billion yen, compared with 59.33 billion yen, posted for the first quarter of 2022.

Selling, general and administrative expenses moved up to 74.85 billion yen, from last year's 47.99 billion yen.

The company registered cost of sales at 558.57 billion yen as against 422.27 billion yen, reported for the first quarter of last fiscal.

Isuzu Motors registered a rise in sales to 688.20 billion yen, from last year's 529.60 billion yen.

Looking ahead, for full-year, the vehicle maker expects a net income of 127.00 billion yen or 163.84 yen per share, with an operating income of 200.00 billion yen, on sales of 3.000 trillion yen.

For the next quarter, the firm intends to pay a dividend of 33 yen per share against last year's dividend of 29 yen per share, with a projection for a year-end dividend of 33 yen per share, compared with last year's 37 yen per share.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT